Discover oncology · 2026
A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Ruihua, Huang Lingjuan, Hao Zhuanghui, Zhao Xue, Dai Jinqian, Gao Qin, Gao Yani
Аннотация
BACKGROUND: Multiple myeloma (MM), the second most common hematological malignancy, is often treated with lenalidomide. However, resistance to this cornerstone therapy inevitably develops in nearly all patients, adversely affecting treatment outcomes and prognosis. To map the knowledge landscape, this study aims to analyze publication trends and identify research hotspots in lenalidomide resistance in MM.
METHODS: A comprehensive search was conducted in the Web of Science Core Collection database from 2005 to 2025. Bibliometric analysis was performed using CiteSpace, VOSviewer, and the R package "bibliometrix" software to identify publication trends, collaborations, and research clusters.
RESULTS: This bibliometric analysis showed sustained growth in publications on MM and lenalidomide resistance. The USA accounted for the largest number of articles (961), followed by China (235) and Italy (183). Harvard University had the largest number of publications among institution (502) whereas Blood had the highest total citation count in this dataset (16,080). Author analysis identified Philippe Moreau as the researcher with the highest H-index. Keyword analysis revealed four major research clusters focusing on combination therapy, cellular mechanisms and apoptosis pathways, proteasome inhibitors, and monoclonal antibodies. Keyword burst analysis revealed "consensus", "phase 3", "open label", "survival outcomes", "oral ixazomib" and "multicenter" since 2020.
CONCLUSION: This bibliometric analysis highlights the rapidly evolving field of lenalidomide resistance in MM. Future efforts should focus on developing next-generation agents against resistance, designing rational combination therapies targeting key pathways like signal transducer and activator of transcription 3 (STAT3)/ nuclear factor kappa-B (NF-κB), and establishing evidence-based treatment consensus to improve outcomes.
METHODS: A comprehensive search was conducted in the Web of Science Core Collection database from 2005 to 2025. Bibliometric analysis was performed using CiteSpace, VOSviewer, and the R package "bibliometrix" software to identify publication trends, collaborations, and research clusters.
RESULTS: This bibliometric analysis showed sustained growth in publications on MM and lenalidomide resistance. The USA accounted for the largest number of articles (961), followed by China (235) and Italy (183). Harvard University had the largest number of publications among institution (502) whereas Blood had the highest total citation count in this dataset (16,080). Author analysis identified Philippe Moreau as the researcher with the highest H-index. Keyword analysis revealed four major research clusters focusing on combination therapy, cellular mechanisms and apoptosis pathways, proteasome inhibitors, and monoclonal antibodies. Keyword burst analysis revealed "consensus", "phase 3", "open label", "survival outcomes", "oral ixazomib" and "multicenter" since 2020.
CONCLUSION: This bibliometric analysis highlights the rapidly evolving field of lenalidomide resistance in MM. Future efforts should focus on developing next-generation agents against resistance, designing rational combination therapies targeting key pathways like signal transducer and activator of transcription 3 (STAT3)/ nuclear factor kappa-B (NF-κB), and establishing evidence-based treatment consensus to improve outcomes.